Mission Statement, Vision, & Core Values of Viveve Medical, Inc. (VIVE)

You want to understand the Mission Statement, Vision, and Core Values of Viveve Medical, Inc. (VIVE), but the real story is how a powerful vision can still hit a financial wall.

How do you square a company's purpose-pioneering women's health solutions-with a November 2025 market capitalization of just $1.08 thousand and a trailing twelve-month (TTM) revenue of $6.82 Million USD? When a company files for Chapter 11 bankruptcy and sells its core assets, does its original mission still hold any weight, or does the acquiring company, InMode Ltd., inherit the strategic blueprint?

Let's look at the foundational beliefs that drove the company and figure out if those values offer any lessons for your own business strategy, even after the asset sale.

Viveve Medical, Inc. (VIVE) Overview

You're looking for the mission and values of Viveve Medical, Inc., but the first thing you need to know is the current reality: the company, as an independent operational entity, is not what it once was. Viveve Medical, Inc. began its journey as Thermagen, Inc. in 2005, evolving into a medical technology firm focused on women's intimate health.

The core of their offering was the Viveve System, a device utilizing patented Cryogen-cooled Monopolar Radiofrequency (CMRF) technology. This system was designed for non-invasive treatments for conditions like vaginal laxity, sexual function, and stress urinary incontinence (SUI), though in the U.S., it was cleared only for general surgical procedures for electrocoagulation and hemostasis.

The company operated on a razor-and-blade model, generating revenue from the initial sale of the Viveve System console and, more importantly, recurring sales of single-use treatment tips. However, following a Chapter 11 bankruptcy filing in late 2023, key assets, including the Viveve System, were acquired by InMode Ltd. in early 2024. The last reported Trailing Twelve Months (TTM) revenue, which reflects the period before the asset sale, stood at approximately $6.83 Million USD as of November 2025.

• Founded: 2005 (as Thermagen, Inc.).
• Core Product: Viveve System (CMRF technology).
• Current Status: Assets sold; no longer an independent operational entity.

Mapping the Financial Reality: 2025 Data Points

Honestly, when we look at the latest financial data points for Viveve Medical, Inc., we aren't seeing record-breaking revenue; we're seeing the fallout from a failed strategy. The company consistently faced significant net losses, which is why it ended up where it is today. For a stark example, in the nine months leading up to September 30, 2023, the company reported a net loss of approximately $18.7 million on revenues of only $3.6 million. That's a massive cash burn that outpaced revenue generation by over 5-to-1.

The most current, albeit sobering, financial metric for the corporate entity is its market capitalization. As of November 21, 2025, the market cap is a mere $1.08 thousand. That's not a company; that's a footnote. The stock price, trading on the OTCMKTS, reflects this reality, sitting at approximately $0.0001 per share. What this estimate hides is the complete cessation of independent operations and the transfer of its main product line to a competitor. You can't analyze growth when the core business has been sold off. Here's the quick math: high operating expenses plus insufficient revenue equals insolvency.

From Innovation to Acquisition: The Industry Footprint

To be fair, Viveve Medical, Inc. was a pioneer in the women's health technology space, specifically with its non-invasive, single-session CMRF technology. They were defintely a leader in innovation, even if they couldn't translate that into sustainable financial performance. Their technology addressed a real, unmet need in the global market, with distribution across the United States, Canada, Asia Pacific, Europe, and Latin America.

The fact that a major player like InMode Ltd. acquired the Viveve System assets in 2024 confirms the underlying value of the technology itself, despite the corporate entity's failure. The technology is still in use, just under a different banner. So, while the corporate shell of Viveve Medical, Inc. is no longer a market leader, its innovative technology continues to impact the industry. To truly understand why the company couldn't sustain its market position, you need to dig into the financial details that led to the bankruptcy. I suggest you find out more by reading Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors.

Viveve Medical, Inc. (VIVE) Mission Statement

You're looking at the mission statement of Viveve Medical, Inc. (VIVE) to understand its strategic compass, but honestly, you have to read this through the lens of a post-mortem. A mission statement is meant to guide long-term goals, but for Viveve Medical, the journey ended in a Chapter 7 liquidation in early 2024, following a Chapter 11 filing in late 2023. The company's historical mission, while noble, failed to translate into a sustainable business model, a sobering lesson for any medical device startup.

The original mission was a clear, three-part commitment: to provide women with low-risk, high-reward medical procedures, to drive innovative technological advances, and to champion global education. This aspirational blueprint is now a historical document, especially since key assets, including the intellectual property for the Viveve System, were acquired by InMode Ltd. in early 2024. The company's current market capitalization, a mere $1.08 thousand as of November 2025, tells you everything you need to know about the outcome of that mission.

Component 1: Pioneering Women's Health and Wellness

The primary component of the mission focused on 'providing women low risk, high reward medical procedures that promote personal health and wellness'. This was the company's market-entry strategy, centered on their Cryogen-cooled Monopolar Radiofrequency (CMRF) technology for conditions like vaginal laxity and stress urinary incontinence (SUI). The core idea was a non-invasive, single-session treatment.

Here's the quick math on the risk side: the company faced significant financial risk, culminating in a bankruptcy filing with total debts reported around $32.7 million versus assets of only $8.5 million. The failure of the pivotal U.S. PURSUIT trial to meet its primary efficacy endpoint for SUI was a critical blow, directly undercutting the 'high reward' claim of the mission. What this estimate hides is the total loss of shareholder equity, with the stock price hovering around $0.0001 in November 2025.

• Focus: Low-risk, high-reward procedures.
• Reality: Clinical trial setbacks eroded the 'high-reward' promise.
• Outcome: Liquidation and asset sale to InMode Ltd..

Component 2: Commitment to Innovative Technological Advances

A seasoned medical technology company must live by its commitment to 'innovative technological advances'. Viveve Medical's innovation was the proprietary Cryogen-cooled Monopolar Radiofrequency (CMRF) technology, which provided volumetric heating while protecting the surface tissue. This technology was their competitive edge, the basis for their razor-and-blade business model with the reusable console and disposable treatment tips.

To be fair, the innovation itself was valuable enough to be acquired. InMode Ltd. purchased the entire intellectual property portfolio, including all worldwide patents, in early 2024. This means the technology survived, but the company that birthed it did not. The innovation was defintely there, but the commercialization strategy and capital management failed to support it. The average annualized stock price for VIVE in 2025 is forecast to be around $0.0002000, which is a stark reminder that technology alone doesn't guarantee a viable business.

Component 3: Global Education and Outreach

The final component was a commitment to 'broad and elucidating education for medical and lay audiences worldwide'. This speaks to the need for market creation in a new medical device category. For a global strategy, you need capital to support a direct sales force and distributor network across the United States, Canada, Asia Pacific, Europe, and Latin America.

The operational reality, however, was a persistent struggle for growth funding in a challenging small-cap medical device environment. The company's trailing twelve-month (TTM) revenue was only $6.83 million as of Q3 2022, a number that couldn't sustain the global infrastructure needed for this kind of broad education and outreach. The mission was too ambitious for the capital they could secure. You can see a deeper dive into the company's past financial struggles here: Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors.

Viveve Medical, Inc. (VIVE) Vision Statement

You're looking at the Vision Statement of Viveve Medical, Inc. (VIVE) as a case study in strategic misalignment, and the direct takeaway is stark: the company's ambitious vision was not realized. By November 2025, the company exists only in name, a shell trading on the OTC market, having filed for Chapter 11 bankruptcy and sold its core assets in late 2023. This is a post-mortem analysis of a vision that failed to withstand financial and operational headwinds.

The historical vision was clear: to be recognized as a global leader in developing and commercializing novel applications of its proprietary radiofrequency technology for women's intimate health. To be fair, that's a powerful, patient-focused goal. But a vision without a sustainable cash flow model is just a wish. Here's the quick math on where that vision landed.

The first component of the vision-to be a 'global leader'-is a clear, quantifiable miss. A global leader commands market share and a significant valuation. As of November 2025, Viveve Medical's stock trades at approximately $0.0001 per share, with a market capitalization (market cap) recently reported around $4.3K. That's not a leader; that's a footnote. The extreme valuation compression throughout 2025 reflects a total loss of investor confidence in the entity's operational sustainability.

For context, the company's net income in the years leading up to its operational collapse consistently showed massive losses, like the net loss of -$22.99 million reported in 2021. You can't lead globally when your financial foundation is crumbling. The market has defintely spoken on this point.

The second part focused on 'developing and commercializing novel applications.' This refers to their core product, the Viveve System, which used cryogen-cooled monopolar radiofrequency (CMRF) technology for conditions like vaginal laxity and stress urinary incontinence (SUI). The business model was a razor-and-blade approach: sell the system (the razor) and then generate recurring revenue from the disposable, single-use treatment tips (the blades).

While the technology was innovative, the commercialization failed. The company's total annual revenue was only $6.43 million in 2021, which isn't enough to sustain the R&D and selling, general, and administrative (SG&A) costs, which were over $22 million that same year. The company's assets were ultimately acquired by another entity, InMode Ltd., meaning the 'novel applications' are now commercialized under a different strategic umbrella.

• Vision was innovative, but execution was capital-intensive.
• High R&D and SG&A costs outpaced modest revenue growth.
• Asset sale confirms commercialization failure for VIVE.

The final pillar was the focus on 'proprietary radiofrequency technology for women's intimate health.' This niche is a high-growth area, but it's also subject to intense regulatory scrutiny and competition. Viveve Medical's technology was proprietary, which is a competitive advantage (a moat), but that moat was not wide enough to offset the cash burn.

The challenge here was capital requirements. Small-cap medical device companies like VIVE need constant funding for clinical trials and regulatory approval processes. When the market loses faith, that funding dries up fast. The persistent market headwinds throughout 2025, combined with the earlier bankruptcy, show that the proprietary nature of the technology couldn't save the entity. The technology itself was the value that was sold off, but the company's ability to maximize that value was nil. You can read more about the financial issues that sank the company here: Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors.

Finance: Review the latest public filings for the acquiring company, InMode Ltd., to track the performance of the acquired Viveve assets, as this is where the technology's true value now lies.

Viveve Medical, Inc. (VIVE) Core Values

You're looking for the current bedrock principles of Viveve Medical, Inc., and honestly, the landscape has changed dramatically. The company, as an independent entity, is effectively defunct, having filed for Chapter 11 bankruptcy in late 2023 and subsequently selling its core assets. The stock's valuation, sitting at a near-zero market capitalization of around $4.29 thousand in November 2025, tells the definitive story of its operational end.

Still, to understand the trajectory that led here, we must look at the historical values that guided its strategy. These values, while aspirational, ultimately clashed with the harsh reality of execution and financial performance. Here's the quick math: the company's inability to convert its mission into sustainable revenue is the core issue.

Commitment to Clinical Innovation

The company's historical mission centered on developing and providing innovative, energy-based solutions. This core value meant a heavy reliance on research and development (R&D) to secure clinical data and regulatory approvals for its proprietary cryogen-cooled monopolar radiofrequency technology. This is a costly business, and the commitment to innovation was clear in the spending.

In the nine months leading up to September 30, 2023, the company's operating expenses, which included R&D and sales/marketing, far outpaced its revenue. The pursuit of clinical proof is expensive; you defintely need a long cash runway for it. The last reported operational snapshot for the nine months ending September 30, 2023, showed a massive net loss of approximately $18.7 million against a mere $3.6 million in revenue. That gap is the financial cost of a clinical innovation strategy that failed to achieve market-scale commercialization.

• Innovation requires capital: R&D costs consistently drained cash.
• Clinical proof: A necessary, but high-risk, investment.
• Outcome: Technology assets sold to InMode Ltd. in 2024.

Advancing Women's Intimate Health

The company's vision was to be a global leader in advancing women's intimate health, focusing on conditions like vaginal introital laxity and stress urinary incontinence (SUI). This value is the heart of its purpose, aiming to improve quality of life through clinically proven treatments.

The commitment here was product-focused, but its impact was ultimately limited by financial failure. The technology itself, the Viveve System, was designed as a non-invasive treatment, a clear attempt to meet a growing market need. But, the inability to achieve profitability or secure further funding-leading to the Chapter 11 filing-meant the mission to 'advance' health was cut short for the company as an independent entity. The technology now lives on under InMode Ltd., which acquired all the worldwide patents, a clear sign that the value of the mission was in the intellectual property, not the organization that created it.

Accountable Financial Stewardship

While not an officially published core value, accountable financial stewardship is a non-negotiable value for any publicly traded company. Its absence here provides the most concrete, actionable lesson for investors. The company consistently faced significant financial challenges, reporting substantial net losses year after year.

The ultimate 2025 data point is a 100% Probability of Bankruptcy as calculated by financial models, which is 131.0% higher than the Health Care Equipment & Supplies sector average. This staggering figure is the final, definitive measure of its commitment to financial health. For any investor, this is the clearest example of a disconnect between an ambitious mission and the necessary fiscal discipline. You can dive deeper into the specifics of this financial distress by Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors.